Chandan Healthca

Why is Chandan Healthcare Ltd falling/rising?

As of 11-Jun, Chandan Healthcare Ltd's stock price is at 224.15, down 1.97%, reflecting a significant decline over various periods, including a 30.94% drop year-to-date. Despite strong fundamentals, the stock continues to underperform, trading below all moving averages and lacking confidence from domestic mutual funds.

As of 11-Jun, Chandan Healthcare Ltd's stock price is falling, currently at 224.15, reflecting a decrease of 4.5 points or 1.97%. This decline is part of a broader trend, as the stock has underperformed significantly over various periods, including a 6.27% drop over the past week and a 10.25% decline over the past month. Year-to-date, the stock has fallen by 30.94%, while the benchmark Sensex has only decreased by 11.36% during the same timeframe.<BR><BR>Today's performance indicates that Chandan Healthcare is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a consistent downward trend in the stock's price. Additionally, despite a rise in delivery volume by 7.76% against the 5-day average, the stock has still underperformed its sector by 1.67%.<BR><BR>While the company has demonstrated strong fundamentals, such as a low Debt to EBITDA ratio of 1.02 and an impressive annual operating profit growth rate of 80.37%, these positive factors have not translated into stock price stability. The flat results reported on March 26 and the lack of investment from domestic mutual funds, which hold 0% of the company, may indicate a lack of confidence in the stock's current valuation or business prospects. Overall, these factors contribute to the current decline in Chandan Healthcare Ltd's stock price.

Which are the latest news on Chandan Healthca?

What does Chandan Healthca do?

Chandan Healthcare Ltd operates advanced laboratories for pathological investigations in the hospital sector, with a market cap of INR 581 Cr. As of March 2026, it reported net sales of 76 Cr and a net profit of 7 Cr.

Overview: <BR>Chandan Healthcare Ltd specializes in operating state-of-the-art laboratories that provide comprehensive pathological investigations within the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Chandan Healthcare Ltd was established on September 03, 2003. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 76 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 7 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 581 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 17.21% <BR>Price to Book: 3.42 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Chandan Healthca?

As of 10th June, Chandan Healthcare Ltd has a market capitalization of 581.00 Cr and reported net sales of 271.14 Cr and net profit of 25.28 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Chandan Healthcare Ltd has a market capitalization of 581.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 271.14 Cr, while the sum of Net Profit for the same period is 25.28 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds stand at 122.60 Cr, and Total Assets are valued at 210.62 Cr.

Who are the peers of the Chandan Healthca?

Chandan Healthcare's peers include Shalby, GPT Healthcare, Unihealth Hospital, and others. It has average management risk, excellent growth, and a 1-year return of 15.35%, lower than Unihealth Hospital's 154.25% but higher than Aprameya Enginee's -8.67%.

Peers: Shalby, GPT Healthcare, Unihealth Hosp, Aprameya Enginee, Lotus Eye Hospit, Vaidya Sane, Asarfi Hospital, KMC Speciality.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Average management risk is found at Shalby, Unihealth Hosp, Chandan Healthca, Vaidya Sane, Asarfi Hospital, and KMC Speciality, and the rest. Growth is Excellent at Unihealth Hosp and Chandan Healthca, while Below Average growth is noted at Shalby, GPT Healthcare, Aprameya Enginee, and the rest. Good capital structure is seen at Shalby, Chandan Healthca, Aprameya Enginee, Lotus Eye Hospit, Asarfi Hospital, and KMC Speciality, while Excellent capital structure is found at GPT Healthcare and Unihealth Hosp.<BR><BR>Return Snapshot: Unihealth Hosp has the highest 1-year return at 154.25%, while Aprameya Enginee has the lowest at -8.67%. Chandan Healthca's 1-year return of 15.35% is higher than Aprameya Enginee's but lower than Unihealth Hosp's. Additionally, the six-month returns are negative for Aprameya Enginee, Vaidya Sane, and KMC Speciality.

How has been the historical performance of Chandan Healthca?

Chandan Healthca has experienced significant growth from March 2023 to March 2025, with net sales increasing from 136.89 Cr to 230.12 Cr and profit after tax rising from 3.59 Cr to 23.52 Cr, despite facing challenges in cash flow management. Total assets grew from 76.12 Cr to 210.62 Cr, indicating a solid financial position.

Answer:<BR>Chandan Healthca has shown significant growth in its financial performance over the past three years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>In terms of net sales, Chandan Healthca increased its revenue from 136.89 Cr in March 2023 to 230.12 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 136.89 Cr to 230.12 Cr during the same period. The company's total expenditure also grew, from 127.51 Cr in March 2023 to 188.79 Cr in March 2025, with notable increases in raw material costs and employee costs. Operating profit, excluding other income, surged from 9.38 Cr in March 2023 to 41.33 Cr in March 2025, indicating improved operational efficiency. Profit before tax rose significantly from 5.01 Cr to 32.06 Cr, and profit after tax increased from 3.59 Cr to 23.52 Cr, showcasing robust profitability growth. The earnings per share (EPS) also improved markedly from 1.69 to 9.07 over the same period. On the balance sheet, total assets grew from 76.12 Cr in March 2022 to 210.62 Cr in March 2025, while total liabilities increased from 42.05 Cr to 56.88 Cr, indicating a solid asset base. Cash flow from operating activities showed a negative trend, moving from a positive 6.00 Cr in March 2022 to a negative 29.00 Cr in March 2025, although net cash inflow remained positive at 2.00 Cr by March 2025. Overall, Chandan Healthca's performance reflects a strong growth trajectory in sales and profitability, despite challenges in cash flow management.

Is Chandan Healthca overvalued or undervalued?

As of August 28, 2025, Chandan Healthcare is considered very expensive and overvalued with a PE ratio of 24.29 and an EV to EBITDA of 13.34, especially compared to peers like Apollo Hospitals and Max Healthcare, and has recently declined by 7.9% against a 2.32% drop in the Sensex, indicating it may not be a favorable investment.

As of 28 August 2025, Chandan Healthcare's valuation grade has moved from fair to very expensive, indicating a significant shift in its market positioning. The company is currently deemed overvalued based on its financial ratios, including a PE ratio of 24.29, an EV to EBITDA of 13.34, and an ROE of 84.79%. These figures suggest that the stock is trading at a premium compared to its earnings and operational efficiency.<BR><BR>In comparison to its peers, Chandan Healthcare's valuation metrics stand out, particularly when contrasted with Apollo Hospitals, which has a PE ratio of 70.56 and an EV to EBITDA of 36.30, and Max Healthcare, which has a PE ratio of 93.61. This highlights that Chandan Healthcare is not only overvalued but also significantly more expensive relative to its competitors in the hospital industry. Furthermore, the recent stock performance shows a decline of 7.9% over the past week, while the Sensex only fell by 2.32%, reinforcing the notion that Chandan Healthcare may not be a favorable investment at its current valuation.

Who are the top shareholders of the Chandan Healthca?

The top shareholders of Chandan Healthcare include Amaranita Holdings (India) Private Limited with 16.87%, 11 Foreign Institutional Investors holding 3.86%, and Negen Undiscovered Value Fund at 3.16%. Individual investors own 33.0% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Chandan Healthcare include several key players. The majority of the shares are held by promoters, with Amaranita Holdings (India) Private Limited being the largest promoter, holding 16.87%. Additionally, there are 11 Foreign Institutional Investors (FIIs) that collectively hold 3.86% of the company's shares. The highest public shareholder is Negen Undiscovered Value Fund, which holds 3.16%. Individual investors collectively own 33.0% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

When is the next results date for Chandan Healthca?

No Upcoming Board Meetings

Has Chandan Healthca declared dividend?

No Dividend History Available